Intercept Pharmaceuticals, Inc. (ICPT) EPS Estimated At $-3.42; National Beverage Has 1.59 Sentiment

April 17, 2018 - By Winifred Garcia

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

Analysts expect Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report $-3.42 EPS on May, 3.They anticipate $0.19 EPS change or 5.26% from last quarter’s $-3.61 EPS. After having $-4.43 EPS previously, Intercept Pharmaceuticals, Inc.’s analysts see -22.80% EPS growth. The stock increased 1.44% or $1.07 during the last trading session, reaching $75.17. About 234,283 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 48.35% since April 17, 2017 and is downtrending. It has underperformed by 59.90% the S&P500.

National Beverage Corp (FIZZ) investors sentiment increased to 1.59 in Q4 2017. It’s up 0.76, from 0.83 in 2017Q3. The ratio has increased, as 100 investment managers started new and increased equity positions, while 63 decreased and sold their holdings in National Beverage Corp. The investment managers in our database now own: 10.83 million shares, up from 9.82 million shares in 2017Q3. Also, the number of investment managers holding National Beverage Corp in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 23 Reduced: 40 Increased: 49 New Position: 51.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $2.21 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals had 73 analyst reports since August 10, 2015 according to SRatingsIntel. Wedbush maintained it with “Outperform” rating and $239 target in Wednesday, June 1 report. The firm earned “Sell” rating on Tuesday, September 12 by Cantor Fitzgerald. The rating was downgraded by Goldman Sachs on Wednesday, February 7 to “Sell”. Wells Fargo initiated Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Friday, December 4 with “Market Perform” rating. The company was maintained on Thursday, November 16 by Wedbush. On Thursday, September 17 the stock rating was upgraded by Vetr to “Strong-Buy”. The firm has “Buy” rating by Cowen & Co given on Monday, June 12. Cowen & Co maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Tuesday, May 31 with “Outperform” rating. JMP Securities maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Tuesday, May 31. JMP Securities has “Market Outperform” rating and $200 target. As per Monday, August 10, the company rating was maintained by Wedbush.

Investors sentiment decreased to 1.31 in Q4 2017. Its down 0.02, from 1.33 in 2017Q3. It turned negative, as 19 investors sold Intercept Pharmaceuticals, Inc. shares while 42 reduced holdings. 36 funds opened positions while 44 raised stakes. 17.97 million shares or 1.43% less from 18.23 million shares in 2017Q3 were reported. 3,903 were reported by Natixis. Blackrock Inc stated it has 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Wells Fargo & Com Mn has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Columbia Wanger Asset Ltd Liability reported 0.1% stake. Panagora Asset Mngmt accumulated 2,427 shares. Bnp Paribas Arbitrage holds 0% or 14,879 shares. Hall Laurie J Trustee holds 60 shares. Us Bankshares De has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Moreover, Spark Investment Mgmt Limited Liability Company has 0.57% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 181,110 shares. Great West Life Assurance Company Can reported 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Sarissa Cap Mngmt Lp owns 182,300 shares for 2.73% of their portfolio. Morgan Stanley invested in 424,019 shares or 0.01% of the stock. State Board Of Administration Of Florida Retirement Systems reported 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Jpmorgan Chase And invested 0.02% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Cubist Systematic Strategies Ltd Llc has 0.01% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

The stock decreased 1.83% or $1.69 during the last trading session, reaching $90.83. About 95,896 shares traded. National Beverage Corp. (FIZZ) has risen 7.39% since April 17, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.

National Beverage Corp., through its subsidiaries, develops, produces, markets, and sells a portfolio of flavored beverage products in North America and internationally. The company has market cap of $4.23 billion. The firm offers beverages to the active and health-conscious consumers, including sparkling waters under the LaCroix, LaCroix Cúrate, LaCroix NiCola, and Shasta Sparkling Water brand names; energy drinks and shots under the Rip It brand name; juice and juice products under the Everfresh, Everfresh Premier Varietals, and Mr. It has a 29.88 P/E ratio. Pure brand names; and carbonated soft drinks in various flavors comprising regular, sugar-free, and reduced-calorie options under the Shasta and Faygo brands.

Covey Capital Advisors Llc holds 0.99% of its portfolio in National Beverage Corp. for 7,700 shares. Navellier & Associates Inc owns 32,635 shares or 0.59% of their US portfolio. Moreover, Kayne Anderson Rudnick Investment Management Llc has 0.54% invested in the company for 677,183 shares. The Massachusetts-based Capital Impact Advisors Llc has invested 0.46% in the stock. Hrt Financial Llc, a New York-based fund reported 4,460 shares.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: